DEF: Bolt Biotherapeutics Schedules 2026 Annual Meeting

Bolt Biotherapeutics announces its 2026 Annual Meeting of Stockholders, to be held virtually on June 10, 2026, with key proposals including director elections and auditor ratification.

Summary

• Bolt Biotherapeutics, Inc. is holding its 2026 Annual Meeting of Stockholders on June 10, 2026, at 11:00 a.m. Pacific Time.
• The meeting will be conducted entirely online, accessible via www.proxydocs.com/BOLT.
• Key business items include the election of two Class II directors, ratification of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2026, and any other business properly brought before the meeting.
• The record date for determining stockholders entitled to vote is April 22, 2026.
• The Board of Directors recommends voting FOR the election of the director nominees and FOR the ratification of the independent auditor.
• Proxy materials, including the Proxy Statement and the Annual Report on Form 10-K for the year ended December 31, 2025, are available online.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it primarily concerns procedural matters for the annual meeting and does not contain new financial performance data or strategic shifts.

Positives

• The company is holding its annual meeting to ensure shareholder engagement and governance.
• The virtual format allows for broader participation regardless of location.
• The Board of Directors is recommending favorable votes for director nominees and auditor ratification, indicating confidence in current leadership and financial oversight.
• The company is providing clear instructions for accessing proxy materials and voting, facilitating shareholder participation.

Negatives

• The filing mentions that Laura Berner, Jakob Dupont, M.D., Kathleen LaPorte, Brian O'Callaghan, and Nicole Onetto, M.D. did not timely file a Form 4 with respect to one transaction, indicating a minor compliance issue with Section 16(a) reporting.
• The company's 2025 audit fees were $855,000, a decrease from $990,000 in 2024, which could reflect cost-saving measures or a reduction in audit scope, though the reason is not explicitly stated.

Risks

• The election of directors is subject to a plurality voting standard, meaning nominees with the most votes are elected, which could lead to a director being elected with less than majority support.
• Abstentions on Proposal 2 (ratification of auditor) will be counted as votes against, potentially impacting the ratification outcome.
• The company's bylaws require advance notice for stockholder proposals or director nominations for future meetings, which could limit the ability of shareholders to introduce new business without prior planning.
• The company has a history of late Section 16(a) filings for some directors, indicating potential ongoing compliance challenges.

Future Outlook

The filing does not contain specific forward-looking financial guidance. It focuses on the procedural aspects of the upcoming annual meeting, including the election of directors and ratification of the auditor.

Management Comments

• "Your vote is very important. Whether or not you attend the 2026 Annual Meeting of Stockholders (by logging into www.proxydocs.com/BOLT ), it is important that your shares be represented."
• "We encourage you to read the accompanying Proxy Statement and our Annual Report on Form 10-K for the year ended December 31, 2025, and submit your proxy on the internet, by phone or by mail in accordance with the instructions in the Notice of Internet Availability of Proxy Materials or your proxy materials."
• "On behalf of the Board of Directors, thank you for your participation in this important annual process."

Industry Context

StockSavvy.ai notes that this filing is a standard proxy statement for an annual meeting, a common occurrence for publicly traded companies. The focus on director elections and auditor ratification reflects typical corporate governance practices within the biotechnology sector.

Comparison to Industry Standards

• The virtual meeting format is increasingly becoming an industry standard, adopted by many companies to enhance accessibility and reduce costs.
• The election of directors with a plurality voting standard is a common practice across U.S. public companies.
• The ratification of PricewaterhouseCoopers LLP as the independent auditor aligns with the use of Big Four accounting firms by many companies in the life sciences industry for financial audits.

Corporate Governance

Legal Proceedings

• There are no specific legal proceedings mentioned in this filing.
• The filing notes that Laura Berner, Jakob Dupont, M.D., Kathleen LaPorte, Brian O'Callaghan, and Nicole Onetto, M.D. did not timely file a Form 4 with respect to one transaction, indicating a minor compliance issue with Section 16(a) reporting requirements.

Related Party Transactions

• Dr. Jakob Dupont provided consulting services as a Senior Clinical Advisor from April 2025 to February 2026, for which he received stock options and hourly compensation totaling $161,500.
• Payments were made to Stanford University for license fees and patent expense reimbursement ($91,800 in 2024, $62,200 in 2025). Dr. Engleman, a former board member and co-inventor of licensed patents, is entitled to a share of royalties, though none have been paid to date.

Stakeholder Impact

• Shareholders: Will vote on director elections and auditor ratification, influencing company leadership and financial oversight. The virtual meeting format aims to increase accessibility for all shareholders.
• Management: Subject to director elections and oversight by an independent board. Compensation is detailed, with performance-based bonuses and equity awards.
• Auditors (PricewaterhouseCoopers LLP): Seeking ratification for the upcoming fiscal year, indicating continued engagement.
• Employees: Eligible for 401(k) matching contributions and other standard employee benefits. Executive compensation details are provided.

Next Steps

• Stockholders are encouraged to vote their shares by internet, phone, or mail prior to the meeting.
• The 2026 Annual Meeting of Stockholders will be held virtually on June 10, 2026.
• Final voting results will be published in a Form 8-K within four business days following the meeting.

Key Dates

Recommendation

This filing is a routine proxy statement for an annual meeting and does not contain new financial performance data, strategic updates, or significant corporate events that would warrant a buy or sell recommendation. It confirms ongoing governance practices and upcoming procedural matters.

Keywords

Proxy Statement, Annual Meeting, Bolt Biotherapeutics, Director Election, Auditor Ratification, Stockholder Vote, Corporate Governance, SEC Filing, DEF 14A